Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|12 CitationsImmunity & GutFemale-friendly

Thymalin Dosing Protocol: Thymus Peptide Guide

Also known as: Thymus Polypeptide Complex, Khavinson Thymic Extract

Dose Range
5–10 mgResearch range
0Typical research window: 5–10 mg12.5 mg

Studied in published research — not a medical recommendation. Primary protocol (Immune Support Protocol): 5-10 mg, Daily for 3-5 days, then weekly.

Protocol at a Glance
How Often
2–3× weekly

Daily for 3-5 days, then weekly

A Typical Run
2-4 week cycles

Used for immune restoration in various conditions

How It's Taken
Vial

Intramuscular or subcutaneous

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

20 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 10 mg in every mL (100 mcg per unit)
0u10u20u30u40u50u
Low end: 5 mg50 units
High end: 10 mg100 units

All U-100: 100 units = 1 mL. 4 doses in the vial at the low end (2 doses at the high end).

Track the doses you run

Save Thymalin to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Research / Non-FDATier 2 — Human Phase 1/2 Clinical Data
Pharmacological Class
Khavinson Short-Chain Epigenetic Organ Bioregulator Peptide (2–4 AA)
Administration Route
Under-the-skin injection (Intramuscular or subcutaneous)
2026 FDA & 503A Status
Unapproved investigational compound in the US; not listed on the FDA 503A Bulk Drug Substances positive list. Available for laboratory research with third-party HPLC + LC-MS COA verification.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 2 — Human Phase 1/2 Clinical Data: Published human Phase 1/2 clinical studies, regional regulatory approval, or controlled human biomarker trials
What is a Bioregulator?

A short peptide (typically 2-4 amino acids) that regulates the function of a specific organ or system. Developed by Russian scientist Vladimir Khavinson through decades of research. Examples include Epithalon (pineal gland), Thymalin (thymus/immune), and Vilon (immune system). Bioregulators are a subset of peptides.

Bottom Line Up Front

Thymalin is a thymus gland bioregulator that supports immune function. It normalizes T-cell mediated immunity. Developed by Khavinson. Used clinically in Russia for immune dysfunction.

Best evidence for

Immune modulation, thymus function

Weakest evidence for

Autoimmune conditions, cancer treatment

Pharma equivalent

None

Studies on file

12 (10 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Thymalin is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Thymalin is a polypeptide complex isolated from the thymus gland that regulates immune function and T-cell differentiation. It contains short peptides EW, KE, and EDP that stimulate thymic function.

Mechanisms of Action

  • Stimulates differentiation and maturation of T-cells
  • Regulates activity of natural killer cells and dendritic cells
  • Contains active peptides EW, KE, and EDP
  • Supports thymic function which declines with age

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Immune Support Protocol
clinical trial
5-10 mgDaily for 3-5 days, then weekly2-4 week cyclesIntramuscular or subcutaneoushuman
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (Thymalin)

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

10 Human2 Animal

Herein, we summarize research progression in the field of thymus-mediated immunoendocrine control of cancer, providing insights into how manipulation of the thymic microenvironment can influence treatment outcomes, including clinical responses and adverse effects of therapies. We review data obtained from clinical and preclinical cancer research to evidence the complexity of immunoendocrine interactions underpinning anti-tumor immunity.

Limitations: No placebo control reported. Review article — no new primary data.

2023|Frontiers in endocrinology
PubMed

We propose that these peptides may form a link between somatic cells and immune as well as neuroendocrine systems. This model may provide a better understanding of the mechanisms underlying immune homeostasis, leading thereby to the development of new therapeutic regimes utilizing the characteristics of thymic peptides.

Limitations: No placebo control reported. Review article — no new primary data.

2021|Expert opinion on biological therapy
PubMed

It is possible that the antiviral effect of thymalin consists in compensatory stimulation of HSC differentiation into CD28+T lymphocytes at the stage of immunity suppression in unfavorable course of viral infection. Thymalin can be considered as an immunoprotective peptide drug for the prevention of COVID-19.

Limitations: No placebo control reported.

2020|Bulletin of experimental biology and medicine
PubMed

Summing up, this article briefly reviews the publications on the physiology of the thymulin-neuroendocrine axis and the anti-inflammatory properties of the molecule and its analog. The availability of novel biotechnological tools should boost basic studies on the molecular biology of thymulin and should also allow an assessment of the potential of gene therapy to restore circulating thymulin levels in thymodeficient animal models and eventually, in humans.

Limitations: No placebo control reported. Review article — no new primary data.

2015|Current pharmaceutical design
PubMed

This regulation may be mediated through thymic hormone effects on peripheral immune cell activities and bidirectional coupling between thymic hormones and the hypothalamic-pituitary-adrenal axis. TAKE-HOME MESSAGE: In view of the role of thymic hormones in immune and neuroendocrine systems, they could be suitable as therapeutic agents for inflammation.

Limitations: No placebo control reported. Review article — no new primary data.

2010|Expert opinion on therapeutic targets
PubMed

We have already shown that Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide first described and characterized by Allan Goldstein in 1972, by modulating signals delivered through innate immune receptors on dendritic cells, affects adaptive immune responses via modulation of Th cell effector and regulatory functions. We will discuss recent molecular mechanisms underlying the ability of Talpha1 to activate or inhibit immune responses.

Limitations: No placebo control reported. Review article — no new primary data.

2010|Annals of the New York Academy of Sciences
PubMed

The enhanced production of neuroendocrine cytokines may affect hormone secretion, neurotransmission, and the development of certain neurodegenerative disorders (e.g., Alzheimer's disease). The isolation of the active component of TF5 that inhibits neuroendocrine and hematopoietic tumor cell proliferation will provide a potential therapeutic strategy for the treatment of these tumors.

Limitations: No placebo control reported. Review article — no new primary data.

2001|Annals of the New York Academy of Sciences
PubMed

These results demonstrate that TP can protect vascular endothelial cells from oxidant injury. The data thus suggest that TP may be useful for the prevention and/or treatment of atherosclerosis, and further suggest that immune modulating agents may directly or indirectly influence the functions of vascular endothelium.

Limitations: Animal study only — human translation uncertain.

1993|Life sciences
PubMed

On the one hand, the studies demonstrated wide potentialities of the use of thymaline in the treatment of the resistant patterns of schizophrenia. On the other hand, they showed the heterogeneity of immune abnormalities in patients with different varieties of resistance.

Limitations: No placebo control reported.

1990|Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)
PubMed

Finally, no VIP-like immunoreactivity was detected in the thymic peptide extract using an antiserum raised against mammalian VIP. All these data suggest the presence in the bovine thymic peptide extract of a new substance which behaves as a VIP agonist in rat.

Limitations: Animal study only — human translation uncertain.

1986|Bioscience reports
PubMed

The effects, in vitro of thymic factors, on peripheral blood lymphocytes isolated from normal donors and patients with primary immunodeficiency disorders, autoimmune disorders, and neoplastic disorders will also be reviewed. Finally, a detailed critical summary of the clinical trials performed with each of the thymic preparations will be presented with an emphasis on treatment of patients with cancer.

Limitations: No placebo control reported. Review article — no new primary data.

1985|Critical reviews in oncology/hematology
PubMed

A preliminary account is reported of the experiments performed with the aim of raising conventional rabbit antisera to the peptide analogue ACTH 1-17, as well as of the consistently negative results which were obtained when 578 human serum samples (from patients treated with such synthetic peptide) were screened by a radioimmunoassay for the occurrence of anti-ACTH 1-17 antibodies. It is emphasized that the recognition of the rhythmic variations of several immunological mechanisms and of the crucial role played by the analogues of adrenal corticotropic and thymic hormones in immune regulation has favoured significant advances in the fast growing area of chronoimmunology.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported. Review article — no new primary data.

1984|La Ricerca in clinica e in laboratorio
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •May cause injection site reactions
  • •Not FDA approved
  • •Use caution in autoimmune conditions
  • •Limited long-term safety data
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Thymalin, baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Trusted Voices

X/Twitter accounts discussing this peptide

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.